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ABSTRACT
Nicotinamide adenine dinucleotide (NAD) is a key molecule in several cellular processes and is
essential for healthy mitochondrial metabolism. We recently reported that mitochondrial
dysfunction is among the very first changes to occur within retinal ganglion cells during initiation of
glaucoma in DBA/2J mice. Furthermore, we demonstrated that an age-dependent decline of NAD
contributes to mitochondrial dysfunction and vulnerability to glaucoma. The decrease in NAD
renders retinal ganglion cells vulnerable to a metabolic crisis following periods of high intraocular
pressure. Treating mice with the NAD precursor nicotinamide (the amide form of vitamin B3)
inhibited many age- and high intraocular pressure- dependent changes with the highest tested
dose decreasing the likelihood of developing glaucoma by »10-fold. In this communication, we
present further evidence of the neuroprotective effects of nicotinamide against glaucoma in mice,
including its prevention of optic nerve excavation and axon loss as assessed by histologic analysis
and axon counting. We also show analyses of age- and intraocular pressure- dependent changes in
transcripts of NAD producing enzymes within retinal ganglion cells and that nicotinamide





ganglion cell; optic nerve
head cupping
Glaucoma represents a significant economic and health
burden. Affecting »80 million people, it is a leading
cause of irreversible vision loss.1 Glaucoma is character-
ized by the progressive dysfunction and loss of retinal
ganglion cells (RGCs) and their axons, which make up
the neural tissue of the optic nerve. Major risk factors for
glaucoma include genetics, elevated intraocular pressure
(IOP), and age. The DBA/2J (D2) mouse is a widely used
model of age-related, hereditary glaucoma, and recapitu-
lates hallmark features of the human disease, including
an insult to axons within the optic nerve. In D2 mice,
mutant alleles of 2 genes (GpnmbR250X, Tyrp1b) cause a
progressive, pigment dispersing, iris disease that results
in an age-related, and asynchronous, ocular hypertension
(beginning at 6 months of age in our colony). Following
a period of IOP elevation, degeneration of the optic nerve
occurs from »10 months of age onwards and this is
almost complete by 12 months of age (»70% nerves
have severe damage).2-6
We recently used RNA-sequencing (RNA-seq) to ana-
lyze D2 RGCs at different ages to elucidate the earliest
molecular changes that occur in glaucoma.7 We identified
mitochondrial dysfunction as one of the first changes
within RGCs. These results guided metabolic profiling
studies that identified an age-dependent depletion of NAD
as a primary driver of RGC vulnerability in glaucoma.
Repleting NAD levels, using a diet supplemented in nico-
tinamide (NAM; an NAD precursor), profoundly pro-
tected from glaucoma (»25% of nerves have severe
damage. [550 mg/kg/d nicotinamide added to regular
drinking water.]).7 This treatment protected from synapse
loss, RGC loss (assessed by soma counts), and optic nerve
degeneration. It also protected from declines in RGC elec-
trical activity as assessed by pattern electroretinography
(PERG) and loss of anterograde axon transport. Impor-
tantly, the treatment prevented mitochondrial changes,
and the transcriptional profiles of nicotinamide-treated
D2 RGCs match those of no glaucoma controls. As PERG
and transcriptional changes are very sensitive measures of
dysfunction these data indicate that nicotinamide mediates
a remarkably robust protection. We provided further evi-
dence of robust protection from glaucoma in mice with
genetically increased NAD levels (increased by the WldS
allele), including protection from decreases in both the
dendritic field area and branching complexity of RGCs as
well as synaptic preservation out to older ages.8,9 To pres-
ent additional evidence for nicotinamide-mediated protec-
tion, we include here results from axon counting and optic
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nerve head analyses. These data demonstrate that nicotin-
amide-treated nerves that show no nerve damage are as
healthy as non-glaucomatous age-matched controls in
terms of their cross sectional area, axon number, and
general morphology, without obvious glial changes
(Fig. 1). Nicotinamide-treated eyes were also protected
from the remodeling and atrophy of the optic nerve head
that produces optic nerve cupping, a characteristic feature
of human glaucoma (Fig. 2). These findings extend
previous studies implicating mitochondria in glaucoma by
showing that mitochondrial dysfunction is among the first
glaucoma initiating changes within RGCs and that NAD
boosting therapy is potently protective.10-13
NAD is a critical cofactor for enzymes in many cellu-
lar processes and is a key metabolic modulator during
aging.14-18 It acts as an oxidizing agent (as NADC) and
as a reducing agent (as NADH). Cellular NAD levels are
maintained through de novo synthesis and by recycling
the by-products of NAD catabolism (Fig. 3A). Sufficient
NAD can be produced through de novo synthesis from
tryptophan in an 8-step pathway. Alternatively NAD can
be produced from vitamin B3. In the literature, vitamin
B3 is considered to be either nicotinic acid (NA) or nico-
tinamide (NAM), and more recently nicotinamide ribo-
side (NR). NAM and NR can be converted to NA in the
gut by bacteria. There are salvage pathway routes for
NAD production through either NAM or NR that recy-
cle NAD from NAD consuming reactions. Specifically,
NAM is a major by-product of NAD catabolism and cells
are equipped to replenish NAD levels using NAM
(Fig. 3A). In fact, NAM is a major precursor of NAD in
vivo when available in large doses.19 In the NAM salvage
pathway, nicotinamide mononucleotide (NMN) is pro-
duced from NAM by the rate-limiting enzyme NAMPT,
Figure 1. NAM prevents optic nerve atrophy and axon loss in glaucoma. Optic nerves from control (D2-GpnmbC; A), DBA/2J (D2; B), and
treated (D2 C NAMLo, D2 C NAMHi; (C) and D) mice were sectioned and stained with PPD, which darkly stains the axoplasm of dead or
dying axons. Surviving axons were counted using AxonJ (E) and optic nerve cross sectional area measured (F). There is a significant
decrease in total axon number and optic nerve area in glaucomatous D2 eyes compared with controls. Nerves from NAM treated mice
are indistinguishable from no glaucoma controls. Nerves were assessed at 12 months of age. NAMLo and NAMHi refer to our low and
high dose of NAM.7 Scale bar D 100 mm (A) and 30 mm (insets).  P < 0.05,  P < 0.01,  P < 0.001.
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and in turn NMN is metabolized to NAD by the spatially
restricted enzymes NMNAT1,¡2, and¡3. Alternatively,
NR is converted into NAD through either a 2-step reac-
tion through the nicotinamide riboside kinase (NRK;
NRK1, ¡2) pathway, or through a 3-step reaction
through phosphorylation to NAM.20 Because declining
NAD levels are thought to be a predisposing factor for
age–related changes and neurodegeneration,15,20 there is
increasing interest in using NAM or NR to increase
NAD levels in various human tissues.
Variations in the level or control of NAD produc-
ing pathways in the retina may impact vulnerability
to glaucoma, as may age-related changes in NAM
(NAM is both a product and endogenous inhibitor of
NAD catabolizing enzymes). The genes encoding the
cellular machinery that drive NAD production from
NAM are expressed in retinal ganglion cells (Nampt,
Nmnat1, Nmnat2, and Nmnat3) however, transcript
abundance of NRK genes (Nmrk1, Nmrk2) that pro-
duce NAD from NR are only lowly expressed in reti-
nal ganglion cells.7 Since age-dependent changes in
gene expression may modulate glaucoma susceptibil-
ity, we have assessed the effects of aging on genes
impacting NAD levels. Importantly, there are age-
dependent declines in the expression of Nmnat2 and
Nampt, and an age-dependent increase in Nadk
(whose encoded enzyme converts NAD to NADP)
within retinal ganglion cells (Fig. 3B). Nmnat2 is the
only NAD-related transcript that we observed to
decline in both an age- and IOP- dependent manner
(Fig. 3C). All these changes are prevented by nicotin-
amide treatment.7
Figure 2. NAM prevents optic nerve cupping in glaucoma. The presence of optic nerve cupping was assessed using haematoxylin and
eosin staining (H & E) and cresyl violet staining (Nissl). In control eyes (D2-GpnmbC) there is a robust ganglion cell layer and nerve fiber
layer (which contains axons from the retinal ganglion cells, denoted by the distance between the black arrows). In D2 eyes that have
undergone glaucomatous neurodegeneration there is evident optic nerve cupping (asterisk), and a loss of ganglion cell layer cells and
nerve fiber layer thickness. Cupping and RGC loss were absent in eyes of NAM treated mice (D2 C NAMLo), thus NAM treatment pro-
tected from all assessed signs of glaucoma. Eyes were assessed at 12 months of age. V corresponds to the central retinal vessel. GCL D
ganglion cell layer, IPL D inner plexiform layer, INL D inner nuclear layer, OPL D outer plexiform layer, ONL D outer nuclear layer. Scale
bar D 50 mm.
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The decreased levels of Nampt and Nmnat2 in retinal
ganglion cells may be a key feature permitting degenera-
tion in this glaucoma. These decreases are expected to, in
turn, decrease the capacity of the salvage pathway in reti-
nal ganglion cells and decrease retinal NAD levels. In
our D2 glaucoma experiments we tested viral gene ther-
apy overexpressing the salvage pathway enzyme
Nmnat1.7 In this gene therapy experiment the entire
gene of interest (Nmnat1) was overexpressed. The
nuclear localization signal (NLS) was intact, and so the
protein product (NMNAT1) should be localized pre-
dominantly at the nucleus within the soma. Poly ADP
ribose polymerase (PARP) increases in RGCs during
pre-degenerative stages of DBA/2J glaucoma.7 Since
PARP depletes nuclear NAD and the NMNAT1 NLS
was intact, it seems most likely that NAD-mediated pro-
tection is mediated within the soma. However, and possi-
bly arguing against this, a critical insult directly damages
RGC axons in glaucoma and keeping cell bodies alive
with a BAX mutation does not save the axons.21
Figure 3. NAD synthesis and NAD relevant genes in RGCs. (A) NAD synthesis. Tryptophan (Trp) is used to form NADC de novo from diet
in an 8 step pathway with nicotinic acid mononucleotide (NAMN) and nicotinic acid adenine dinucleotide (NAADC) intermediates. Alter-
natively NADC can be produced through 2 other core pathways; the Preiss-Handler pathway from nicotinic acid (NA), or through the sal-
vage pathway from nicotinamide (NAM). NA is used in the Preiss-Handler pathway to form NADC via 2 steps shared with the de novo
pathway: NAMN (by nicotinic acid phosphoribosyltransferase; NAPRT1) and NAADC (by NADC synthetase; NADSYN1). In the salvage
pathway, NAM is used to form NADC being converted by nicotinamide phosphoribosyltransferase (NAMPT) to nicotinamide mononucle-
otide (NMN) and subsequently to NADC by nicotinamide nucleotide adenylytransferase (NMNAT1, ¡2, and ¡3). NAM can also be con-
verted to NA in the gut by bacterial PncA (nicotinamidase) and salvaged into the Preiss-Handler pathway. NAM is available in diet, but
can also be produced by NADC-consuming enzymes. Nicotinamide riboside (NR) can feed into the salvage pathway to form NADC by
nicotinamide riboside kinases (NRK1, ¡2; Nmrk1, ¡2 as mouse genes) via NMN, or via NAM by purine nucleoside phosphorylase (NP).
(B) and (C) Retinal ganglion cells exhibit age-dependent changes in NADC synthesis-related genes as well as further IOP-dependent
declines in Nmnat2, an important NAD producing enzyme linked to axon protection. The decline in NAD is a major age-dependent risk
factor for DBA/2J glaucoma. NADK (Nadk gene) is a major NAD-consuming kinase and its upregulation suggests increased NAD con-
sumption / utilization. Differentially expressed genes (FDR < 0.05) are shown in red. Non-differentially expressed genes are shown in
gray.
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Interestingly, NMNAT1 with an intact NLS does not
protect axons in transgenic mice arguing that NMNAT1
must reach the axon to be protective.22 cytNmnat1, an
NMNAT1 mutant that localizes only to the cytoplasm
(and thus axon) provides potent axon protection in
transgenic mice.23 Soma, axons, and terminal projections
in the brain were protected in our experiments and
together, this may argue that NAM, and possibly the
virally produced NMNAT1, has protective effects within
the axon. It is also possible that overexpression drives
some virally produced NMNAT1 (with intact NLS) into
axons but this has yet to be empirically tested. If meta-
bolic compromise within the soma is necessary to allow
the axons to be insulted, however, it is possible that pre-
serving somal metabolism may also preserve the axons.
Thus, our data suggest that maintaining somal health
and metabolism can prevent axon degeneration in glau-
coma - an axonopathy where it is clear that a critical
insult directly attacks axons in the optic nerve head.24 If
the axon can be saved through a soma-targeted mecha-
nism, this raises an exciting prospect for other (especially
distal) axonopathies where it would not be feasible to
treat individual neuronal targets but instead could target
a hub of soma or ganglion. However, a protective effect
within axons cannot be ruled out. NMNAT2 is emerging
as a key NAD producing enzyme within axons.25,26 New
evidence shows wide variability of NMNAT2 transcript
levels between human post-mortem brains.25 Such varia-
tion in human NMNAT2 expression has the potential to
modulate neuronal vulnerability to stresses such as ele-
vated IOP in glaucoma. Nmnat3 has also been detected
in both somas and axons and overexpression of Nmnat3
protects from axon degeneration in other models of
axonopathy and glaucoma.27 Therefore the decreased
abundance of Nmnat2 and Nampt transcripts that we
observed in D2 retinal ganglion cells may underlie meta-
bolic defects in the axon or throughout the entire cell.
Conclusions
In conclusion, retinal ganglion cells undergo age-depen-
dent declines in key NAD-salvage pathway transcripts.
These declines are expected to contribute to a decline of
NAD rendering these cells susceptible to IOP-dependent
stresses. Nicotinamide prevents these changes and
robustly protects all assessed cell compartments. The
mechanisms of how nicotinamide counteracts age- and
IOP- dependent changes and whether other NAD pre-
cursors have the same effects are important areas for
future research. Declining NAD is appearing as a shared
mechanism in aging and neurodegeneration.15,16 As such
an important avenue in future research will be to test
NAD-boosting strategies in other glaucoma models
(especially higher order animal models such as non-
human primate models) as well as in other models of
neurodegenerations. The possibility that a simple dietary
supplement can prevent neurodegeneration is an exciting
prospect with broad implications for age-related diseases.
Methods
Unless stated, methods used have been previously out-
lined.7 RNA-seq data are publically available through the
Gene Expression Omnibus (accession number
GSE90654). For automated axon counts, AxonJ was used
to count the entire cross sectional nerve area at a 63x
magnification for 10 nerves in each experimental
group.28
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